EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Risk of Adverse Pregnancy Outcomes in Patients with Non-Communicable, Chronic Inflammatory Barrier Diseases Under Systemic Treatment: A Large-Scale Retrospective Cohort Study

Inga Catharina Brouer iD, Aida Zani, Philip Curman iD, Ralf J Ludwig, Diamant Thaçi iD

Biomolecules · 24.07.2026 · 16 (8) · 1083

DOI: 10.3390/biom16081083 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Biomolecules, online erschienen am 24.07.2026. Verfasst von Inga Catharina Brouer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, 23562 Lübeck, Germany. Hauptthemen laut MEDLINE: Pregnancy Outcome, Pregnancy Complications, Antirheumatic Agents, Inflammation. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cluster of Excellence Precision Medicine in Chronic Inflammation, Deutsche Forschungsgemeinschaft, Schleswig-Holstein Excellence Chair Program of the State of Schleswig-Holstein.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic inflammatory barrier diseases (CIBDs) affect many women of reproductive age, yet the safety of biologics during pregnancy remains inadequately investigated. This retrospective cohort study used the US Collaborative Network of TriNetX to evaluate the risk of adverse pregnancy outcomes (APOs) among women with CIBD receiving tumor necrosis factor inhibitors (TNFis), interleukin-23 inhibitors (IL-23is), or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), compared with untreated CIBD controls and the general pregnant population. Among 1842 pregnant women with CIBD receiving systemic therapy, 1188 were exposed to TNFis, 170 to IL-23is, 370 to azathioprine (csDMARD), and 114 to methotrexate (MTX) (csDMARD). The incidence of any APO ranged from 11% in untreated CIBD controls to 19% with ustekinumab (IL-12/23i). Among treatment groups, rates were 17% with TNFis, 18% with IL-23is, 13% with azathioprine, and 15% with MTX, compared with 17% in the general pregnant population. APO rates were comparable between the overall TNFi group and the TNFi group excluding certolizumab pegol (CZP) (TNFi). In the only non-exploratory comparison, TNFi exposure was associated with higher risks of (pre-)eclampsia and hypertension but a lower risk of abortion or intrauterine death versus CIBD controls, with no significant difference for overall APO. No treatment group showed a markedly increased overall APO risk, supporting tailored decision-making that balances the consequences of uncontrolled maternal disease against individual treatment-associated risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnancy OutcomePregnancy ComplicationsAntirheumatic AgentsInflammationHumansFemalePregnancyRetrospective StudiesAdultAzathioprineInterleukin-23MethotrexateTumor Necrosis Factor Inhibitors

Stichwörter der Autor:innen

IL-23 inhibitorsTNF inhibitorsadverse pregnancy outcomeschronic inflammatory barrier diseasescsDMARDspregnancy

Substanzen

Antirheumatic AgentsAzathioprineInterleukin-23MethotrexateTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, 23562 Lübeck, Germany.
  • Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Dermatology and Venereology Division, Department of Medicine (Solna), Karolinska Institutet, 17177 Stockholm, Sweden.
  • Dermato-Venereology Clinic, Karolinska University Hospital, 17176 Stockholm, Sweden.
  • Department of Dermatology, University Medical Centre of the State of Schleswig-Holstein (UKSH), 23538 Lübeck, Germany.

ORCID-Profile: Inga Catharina Brouer, Philip Curman, Diamant Thaçi

Förderung

  • Cluster of Excellence Precision Medicine in Chronic Inflammation
  • Deutsche Forschungsgemeinschaft
  • Schleswig-Holstein Excellence Chair Program of the State of Schleswig-Holstein

Zitieren

APA

Brouer, I. C., Zani, A., Curman, P., Ludwig, R. J., & Thaçi, D. (2026). Risk of Adverse Pregnancy Outcomes in Patients with Non-Communicable, Chronic Inflammatory Barrier Diseases Under Systemic Treatment: A Large-Scale Retrospective Cohort Study. Biomolecules, 16(8), 1083. https://doi.org/10.3390/biom16081083

Vancouver

Brouer IC, Zani A, Curman P, Ludwig RJ, Thaçi D. Risk of Adverse Pregnancy Outcomes in Patients with Non-Communicable, Chronic Inflammatory Barrier Diseases Under Systemic Treatment: A Large-Scale Retrospective Cohort Study. Biomolecules. 2026;16(8):1083. doi:10.3390/biom16081083

BibTeX
@article{Brouer2026,
  author = {Brouer, Inga Catharina and Zani, Aida and Curman, Philip and Ludwig, Ralf J and Thaçi, Diamant},
  title = {Risk of Adverse Pregnancy Outcomes in Patients with Non-Communicable, Chronic Inflammatory Barrier Diseases Under Systemic Treatment: A Large-Scale Retrospective Cohort Study},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {1083},
  doi = {10.3390/biom16081083}
}
Kostenlos starten →